Transition from Child and Adolescent to Adult Mental Health Services in Young People with Depression: On What Do Clinicians Base their Recommendation?
- PMID: 40224602
- PMCID: PMC11921827
- DOI: 10.1155/2023/8495521
Transition from Child and Adolescent to Adult Mental Health Services in Young People with Depression: On What Do Clinicians Base their Recommendation?
Abstract
Background: Clinicians in Child and Adolescent Mental Healthcare Services (CAMHS) face the challenge to determine who is at risk of persistence of depressive problems into adulthood and requires continued treatment after reaching the CAMHS upper age limit of care-provision. We assessed whether risk factors for persistence were related to CAMHS clinicians' transition recommendations.
Methods: Within the wider MILESTONE cohort study, 203 CAMHS users were classified with unipolar depressive disorder by their clinician, and 185 reported clinical levels of depressive problems on the DSM-oriented Depressive Problems scale of the Achenbach Youth Self Report. Logistic regression models were fitted to both subsamples to assess the relationship between clinicians' transition recommendations and risk factors for persistent depression.
Results: Only clinician-rated severity of psychopathology was related to a recommendation to continue treatment for those classified with unipolar depressive disorder (N = 203; OR = 1.45, 95% CI (1.03-2.03), p = .044) and for those with self-reported depressive problems on the Achenbach DSM-oriented Depressive Problems scale (N = 185; OR = 1.62, 95% CI (1.12-2.34), p = .012).
Conclusion: Transition recommendations and need for continued treatment are based on clinical expertise, rather than self-reported problems and needs.
Copyright © 2023 Larissa S. van Bodegom et al.
Conflict of interest statement
SPS is part-funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM), now recommissioned as NIHR Applied Research Collaboration West Midlands. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. PS is the coinventor of the HealthTrackerTM, is the Chief Executive Officer and shareholder in HealthTracker Ltd., and has received funding for clinical trials in Rett syndrome from Anavex Scientific Corp., Newron Pharma, and GW Pharma (all not related to transition research). AM was a speaker and advisor for Neurim, Shire, InfectoPharm, and Lilly (all not related to transition research).